Tag Archive for: Oncology

The company announced its experimental personalized mRNA skin cancer vaccine in combination with Merck & Co Inc.’s drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.

Genome engineering company Replay and The University of Texas’ MD Anderson Cancer Center have joined forces to launch Syena, an oncology product company.

As oncology drugs receive accelerated approvals, payers are questioning whether the benefits of these products outweigh the cost, spurring manufacturers to explore value-based agreements.

As pharma marketers, we strive to be patient-centric. We create and analyze patient journeys, conduct in-depth research, and even co-create materials, all with the focus of creating personalized, engaging campaigns that empower and educate patients. Sometimes, though, the science takes a leap of such breadth and scale that it changes the very concept and meaning of patient-centricity.

The combined capabilities will help improve trial lifecycles for patients, sites, and sponsors.

The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies.

As the healthcare journey for patients living with cancer has changed, so has the way in which pharmaceutical companies bring a drug to market. Med Ad News spoke with Anne Marie Robertson, SVP, strategy & marketing, EVERSANA about how companies need to rethink traditional commercialization models in oncology to be agile in today’s market.

To effectively promote your brand, it is important to have a message that stands out and a story that will capture the attention of your target audience. We have utilized oncology message benchmarks to study more than 30,000 interactions between oncologists and sales representatives for over 100 brands to understand what makes them tick.

Findings from the pivotal Phase III NAPOLI 3 trial show Ipsen’s Onivyde (irinotecan liposome injection), when used as part of the investigational NALIRIFOX regimen, boosted overall survival in metastatic pancreatic ductal adenocarcinoma, the company announced Friday.

Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.